Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER vs AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Heparin binds to antithrombin III, causing a conformational change that accelerates the inactivation of thrombin (factor IIa) and activated factor X (factor Xa), thereby inhibiting coagulation.
Aminophylline is a complex of theophylline and ethylenediamine. Theophylline acts as a non-selective phosphodiesterase inhibitor, increasing intracellular cyclic AMP levels, leading to bronchodilation. It also blocks adenosine receptors, stimulates catecholamine release, and enhances diaphragmatic contractility. The ethylenediamine component increases solubility.
Prophylaxis and treatment of deep vein thrombosis (DVT),Prophylaxis and treatment of pulmonary embolism (PE),Anticoagulation for atrial fibrillation with embolization,Treatment of acute coronary syndromes (e.g., unstable angina, myocardial infarction),Anticoagulation in extracorporeal circuits (e.g., hemodialysis, cardiopulmonary bypass)
Treatment of symptoms and reversible airflow obstruction associated with chronic asthma and other chronic lung diseases (e.g., emphysema, chronic bronchitis),Adjunctive therapy in acute bronchial asthma and status asthmaticus,Off-label: Treatment of apnea of prematurity
Adult: IV bolus 5,000 units followed by continuous IV infusion at 1,000 units/hour (25,000-40,000 units/24h) titrated to a PTT 1.5-2.5 times control. Subcutaneous: 5,000 units every 8-12 hours.
Loading dose: 5-6 mg/kg IV over 20-30 minutes (if not on theophylline). Maintenance: 0.5-0.7 mg/kg/h IV continuous infusion.
Terminal elimination half-life is dose-dependent: 0.5–1.5 hours after intravenous administration of 100 U/kg, increasing to 1.5–2.5 hours after 200 U/kg, and up to 3–6 hours after 400 U/kg. Clinically, the anticoagulant effect (a PTT) has a half-life of approximately 1–2 hours, and this is used for dosing adjustments.
Terminal elimination half-life: 3-12 hours in adults (mean 5-6 hours); prolonged in hepatic impairment, heart failure, COPD, and neonates (up to 30 hours). Smoking reduces half-life by 30-50%.
Heparin is primarily cleared via the reticuloendothelial system and undergoes desulfation and depolymerization. A portion is excreted unchanged in urine.
Theophylline is metabolized primarily in the liver by cytochrome P450 isoenzymes, predominantly CYP1A2, with minor contributions from CYP2E1 and CYP3A4. Metabolism involves N-demethylation and oxidation. In neonates, metabolism is immature; in adults, ~90% is hepatically cleared. Ethylenediamine is minimally metabolized.
Renal: Heparin is primarily cleared by the reticuloendothelial system and the liver via desulfation and depolymerization, with metabolites excreted in urine. Only about 50% of an administered dose is excreted unchanged in urine at therapeutic doses; the remainder is metabolized. Biliary/fecal excretion is minimal.
Renal excretion of unchanged drug (about 10-20%) and metabolites (primarily 1,3-dimethyluric acid, 1-methyluric acid, 3-methylxanthine). Billary/fecal excretion is negligible.
Heparin binds extensively to various plasma proteins, including antithrombin III (high affinity), albumin, and other proteins. Overall protein binding is approximately 95%.
Theophylline (active moiety): approximately 40% bound to plasma proteins, primarily albumin. Protein binding decreases in neonates, hepatic cirrhosis, and uremia.
0.06–0.07 L/kg (low, as heparin is largely confined to the intravascular space).
Apparent volume of distribution: approximately 0.4-0.6 L/kg (average 0.45 L/kg). Indicates distribution into total body water; slightly higher in neonates and premature infants.
Subcutaneous: approximately 30–40% (low due to poor absorption and metabolism at injection site). Intravenous: 100%.
Oral: 96-100% for immediate-release tablets; 50-70% for some sustained-release formulations depending on formulation. Rectal: 70-80% (variable). IV: 100%.
No specific GFR-based dose adjustment required; monitor a PTT. In severe renal impairment (Cr Cl <30 m L/min), reduce infusion rate by 20-50% and monitor anti-Xa levels.
No dose adjustment required for GFR >30 m L/min. For GFR 10-30 m L/min: reduce maintenance dose by 50% and monitor serum theophylline levels. For GFR <10 m L/min: reduce maintenance dose by 50% and extend dosing interval or use with caution.
Child-Pugh Class A: No adjustment. Child-Pugh Class B: Reduce dose by 25-50% with close a PTT monitoring. Child-Pugh Class C: Avoid or use with extreme caution; reduce dose by 50-75%.
Child-Pugh A: reduce dose by 50%. Child-Pugh B: reduce dose by 75%. Child-Pugh C: contraindicated or use with extreme caution, reduce dose by 80% and monitor levels.
IV bolus: 50-100 units/kg, then continuous IV infusion: 15-25 units/kg/hour. Titrate to a PTT 60-85 seconds or anti-Xa 0.3-0.7 units/m L.
Loading dose: 1 mg/kg IV (if not on theophylline). Maintenance: Continuous infusion: age 6 months-1 year: 0.5 mg/kg/h; age 1-9 years: 0.8 mg/kg/h; age 9-12 years: 0.7 mg/kg/h; age 12-16 years: 0.6 mg/kg/h. Maximum daily dose: 24 mg/kg/day.
Elderly patients may have reduced clearance; use lower initial infusion rates (e.g., 750 units/hour) and monitor a PTT frequently. Start with 50% of the usual bolus dose in patients >70 years.
Consider lower initial doses due to decreased clearance. Use ideal body weight. Start at lower maintenance infusion rate (e.g., 0.3 mg/kg/h) and titrate based on serum levels and clinical response. Monitor for toxicity.
Heparin is not intended for intramuscular use due to risk of hematoma. Monitor for signs of bleeding, especially in patients with risk factors. Epidural or spinal hematomas may occur with concurrent neuraxial anesthesia or spinal puncture, resulting in long-term or permanent paralysis.
None
Risk of hemorrhage: monitor coagulation parameters (a PTT) and adjust dose accordingly.,Heparin-induced thrombocytopenia (HIT): monitor platelet counts; discontinue if HIT suspected.,Hyperkalemia: heparin suppresses aldosterone synthesis; monitor potassium in high-risk patients.,Osteoporosis with long-term use ( >3 months).,Use with caution in patients with severe hepatic or renal impairment, uncontrolled hypertension, or history of gastrointestinal ulcers.
Narrow therapeutic index; serum theophylline levels must be monitored to avoid toxicity. Risk of seizures, cardiac arrhythmias, and death, especially at high serum concentrations. Caution in patients with hepatic impairment, congestive heart failure, cor pulmonale, fever, and in the elderly. Drug interactions with cimetidine, fluoroquinolones, macrolides, oral contraceptives, and other CYP1A2 inhibitors can increase toxicity.
Active major bleeding (e.g., intracranial, gastrointestinal, retroperitoneal),History of heparin-induced thrombocytopenia (HIT),Severe thrombocytopenia (platelet count <100,000/µL),Hypersensitivity to heparin or porcine products,Known coagulation disorders (e.g., hemophilia, von Willebrand disease),Inability to perform appropriate coagulation monitoring (e.g., a PTT)
Absolute: Hypersensitivity to theophylline, ethylenediamine, or any component; use in patients with active seizure disorder (unless receiving appropriate anticonvulsant therapy); use in patients with a history of ventricular arrhythmias (except under close supervision). Relative: Peptic ulcer disease, hyperthyroidism, hypertension, and renal impairment.
No significant food interactions. However, avoid excessive alcohol consumption as it may increase bleeding risk. Vitamin K-rich foods (e.g., leafy greens) do not affect heparin's anticoagulant effect, in contrast to warfarin.
Avoid large amounts of caffeine-containing foods and beverages (coffee, tea, cola, chocolate) as they can potentiate theophylline effects and increase risk of toxicity. A high-protein diet may increase theophylline clearance; maintain consistent dietary habits.
Heparin is not known to cross the placenta due to its high molecular weight and negative charge, and is not associated with fetal teratogenicity. First trimester: No increased risk of major malformations. Second and third trimesters: No known teratogenic effects; use for treatment or prevention of thrombosis is considered safe. Risk of maternal hemorrhage and placental abruption exists with overdose.
Pregnancy Category C. First trimester: Limited human data; animal studies show no teratogenicity but some developmental delays at high doses. Second and third trimesters: Use only if benefit outweighs risk; may cause fetal tachycardia or irritability due to adenosine receptor blockade. Avoid near term due to potential neonatal irritability.
Heparin is not excreted into breast milk due to its high molecular weight and negative charge, making it compatible with breastfeeding. M/P ratio is not applicable as it is undetectable in milk.
Not recommended unless essential. Aminophylline is excreted into breast milk; M/P ratio approximately 0.6–0.8. Monitor infant for irritability or insomnia. Consider alternative therapies if breastfeeding.
Pregnancy is associated with increased plasma volume, renal clearance, and heparin-binding proteins, which may reduce heparin efficacy. Dose adjustment is often required: a PTT monitoring is mandatory, and doses are typically increased (up to 30-50% higher) to maintain therapeutic levels. Weight-based dosing should account for actual body weight. Postpartum, doses may need reduction due to normalization of clearance.
Pregnancy may decrease protein binding and increase clearance of theophylline; monitor serum levels closely. Dose may need to be increased by 10–30% to maintain therapeutic levels. Postpartum, doses may need reduction.
Use actual body weight for dosing; check a PTT 6 hours after initiation and after dose changes; monitor platelet count for heparin-induced thrombocytopenia (HIT); avoid intramuscular injections during therapy. Protamine sulfate (1 mg per 100 units heparin) reverses effects. For I. V. flushes, use preservative-free formulation when possible.
Aminophylline is a bronchodilator used primarily for asthma and COPD exacerbations. Monitor serum theophylline levels closely due to narrow therapeutic index (10-20 mcg/m L). Administer IV infusion over 30 minutes to avoid hypotension. Caution in patients with cardiac arrhythmias, hyperthyroidism, or seizure disorders. Drug interactions include cimetidine, fluoroquinolones, and macrolides which increase theophylline levels.
Report any unusual bleeding or bruising immediately.,Avoid aspirin, NSAIDs, and other blood thinners unless prescribed.,Inform all healthcare providers (including dentists) that you are on heparin.,Do not take any new medications without consulting your doctor.,Seek medical help if you experience signs of allergic reaction (rash, itching, swelling, severe dizziness, trouble breathing).
Take this medication exactly as prescribed; do not stop or change dose without consulting your doctor.,Avoid excessive caffeine intake (coffee, tea, chocolate, cola) as it may increase side effects like jitteriness and palpitations.,Report any symptoms of toxicity such as nausea, vomiting, insomnia, rapid heart rate, or seizures immediately.,Inform your healthcare provider of all other medications, especially antibiotics, heart medications, or seizure drugs.,Do not chew or crush the solution; it is for intravenous use only under medical supervision.
"Lithium cation may increase the excretion rate of Sodium chloride which could result in a lower serum level and potentially a reduction in efficacy."
"The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan."
"Concurrent administration of aminophylline, a xanthine derivative bronchodilator that is metabolized primarily by CYP1A2 and to a lesser extent CYP3A4, may reduce the clearance of ranolazine, an antianginal agent predominantly metabolized by CYP3A4 and to a lesser extent CYP2D6. Aminophylline can inhibit CYP3A4 activity, leading to increased ranolazine plasma concentrations, which elevates the risk of dose-dependent adverse effects such as QTc prolongation, dizziness, and syncope. This interaction is clinically significant and may necessitate dose adjustment or alternative therapy."
"Asunaprevir, a potent inhibitor of the drug transporter OATP1B1, can significantly decrease the serum concentration of aminophylline, a theophylline salt, likely by reducing its intestinal absorption or increasing its hepatic clearance. This interaction may lead to reduced therapeutic efficacy of aminophylline, potentially worsening respiratory symptoms in patients with asthma or COPD. Close monitoring and dose adjustment of aminophylline are recommended during coadministration with asunaprevir."
"Aminophylline, a bronchodilator, inhibits the metabolism of tibolone, a synthetic steroid hormone used for hormone replacement therapy, primarily through competitive inhibition of cytochrome P450 (CYP) 3A4 isoenzyme. This results in increased plasma concentrations of tibolone and its active metabolites, potentiating its hormonal effects and increasing the risk of adverse events such as thromboembolism, endometrial hyperplasia, or breast tenderness. Clinically, coadministration may require dose adjustments and careful monitoring for signs of estrogenic excess."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER vs AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, answered by our medical review team.
HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is a Electrolyte that works by Heparin binds to antithrombin III, causing a conformational change that accelerates the inactivation of thrombin (factor IIa) and activated factor X (factor Xa), thereby inhibiting coagulation.. AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER is a Electrolyte that works by Aminophylline is a complex of theophylline and ethylenediamine. Theophylline acts as a non-selective phosphodiesterase inhibitor, increasing intracellular cyclic AMP levels, leading to bronchodilation. It also blocks adenosine receptors, stimulates catecholamine release, and enhances diaphragmatic contractility. The ethylenediamine component increases solubility.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER and AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is: Adult: IV bolus 5,000 units followed by continuous IV infusion at 1,000 units/hour (25,000-40,000 units/24h) titrated to a PTT 1.5-2.5 times control. Subcutaneous: 5,000 units every 8-12 hours.. The standard adult dose of AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER is: Loading dose: 5-6 mg/kg IV over 20-30 minutes (if not on theophylline). Maintenance: 0.5-0.7 mg/kg/h IV continuous infusion.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER and AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER. The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is classified as Category A/B. Heparin is not known to cross the placenta due to its high molecular weight and negative charge, and is not associated with fetal teratogenicity. First trimester: No increased risk. AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER is classified as Category A/B. Pregnancy Category C. First trimester: Limited human data; animal studies show no teratogenicity but some developmental delays at high doses. Second and third trimesters: Use only . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.